In focus · trending topic

Rhizen Pharmaceuticals S.A.

3 stories · following the connections

Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA

By Nasdaq OMXDec 5, 2017, 12:00 PM UTC

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA

By Nasdaq OMXOct 24, 2017, 11:00 AM UTC

Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor

By Nasdaq OMXDec 9, 2015, 12:00 PM UTC